# This Page Is Inserted by IFW Operations and is not a part of the Official Record

# BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

# IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau

### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) WO 97/41225

INTERNATIONAL APPLICATION PUBLIS	HED C		WO 97/41225
(51) International Patent Classification 6:	A3	(43)	) International Publication Date: 6 November 1997 (06.11.97)
C12N 15/12, C0/K 14/7/13, C12N 15/11 G01N 33/68, C07K 16/28, C12N 15/11  (21) International Application Number: PCT/US	S97/069	93	(74) Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).
(21) International Application (22) International Filing Date: 25 April 1997	(25.04.9	97)	(81) Designated States: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent
(30) Priority Data: 08/638,081 26 April 1996 (26.04.96)		US	patent (GH, KE, LS, MW, SD, 32, 603).  (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
US 26 April 1996 Filed on		.96)	Published With international search report.
(71) Applicant (for all designated States except US) PHARMACEUTICALS, INC. [US/US]; 3174 F Palo Alto, CA 94304 (US).	: INC Porter D	YTE rive,	(88) Date of publication of the international search report: 23 April 1998 (23.04.98)

(72) Inventors; and
(75) Inventors'Applicants (for US only): AU-YOUNG, Janice (175) Inventors'Applicants (for US only): AU-YOUNG, Janice (US/US); 1419 Kains Avenue, Berkeley, CA 94702 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94041 (US) WILDE (175) WILDE Mariposa #2, Mountain View, CA 94041 (US). WILDE, Craig, G. [US/US]; 1239 Mandarin Drive, Sunnyvale, CA 94087 (US).

(54) Title: MAMMALIAN MIXED LYMPHOCYTE RECEPTORS, CHEMOKINE RECEPTORS (MMLR-CCR)

The present invention provides polynucleotides (mmlr-ccr or mphg-ccr) which encode novel chemokine receptors (MMLR-CCR or The present invention provides polynucleotides (minir-cer or inpug-cer) which encode novel chemokine receptors (MMLR-CCR or MPHG-CCR). The present invention provides for screening methods for the detection of molecules that modulate receptor activity. The (57) Abstract present invention also provides for antisense molecules, diagnostic molecules, genetically engineered expression vectors and host cells for the present invention also provides for antisense molecules, diagnostic molecules, genetically engineered expression vectors and host cells for the present invention also provides for antisense molecules, diagnostic molecules, genetically engineered expression vectors and host cells for the present invention also provides for anusense molecules, diagnostic molecules, genetically engineered expression vectors and nost cells for the production of purified MMLR-CCR or MPHG-CCR; antibodies, agonists, antagonists and inhibitors of MMLR-CCR or MPHG-CCR; and production or purified MMLK-CCK of MPHO-CCK; antibodies, agonisis, antagonists and inhibitors of MPHO-CCK; and pharmaceutical compositions and methods of treatment based on the polypeptide, its antibodies, antagonists and inhibitors. The invention pnarmaceutical compositions and memous of treatment based on the polypeptide, its antibodies, antagonists and innibitors. The invention further provides diagnostic and therapeutic compositions for the detection and treatment of infection, inflammation, proliferative disease, solid tumors and cardiovascular disease.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

DE Germany LK Sri Lanka SK Sweden  DK Denmark LR Liberta SG Singapore  EE Estonia	DK Denmark LR Liberia SG Singapore	
---	------------------------------------	--

Interr \u00e4nat Application No

	INTERNATIONAL SEARCH REPORT	Interr The Application
		PCT/US 97/06993
	C12N15/12 (0/K14//13 012N0/	33/68 C07K16/28
	C12N15/11	_
ordina ta Ini	ternational Patent Classification (IPC) or to both national classification and IPC	
mum docus C 6	ARCHED mentation searched (classification system followed by classification symbols) C07 K	
		1 1 1 1 to fields searched
cumentation	n searched other than minimum documentation to the extent that such documents an	e included to the lieus something
	a base consulted during the international search (name of data base and, where pro	actical, search terms used)
eotronio dat	a base consulted during the attentions.	
	·	
. DOCUME	NT9 CONSIDERED TO BE RELEVANT	Relevant to claim No.
ategory *	NTS CONSIDERED TO BE TIED TO BE T	
	BORING L ET AL: "Molecular cloning and	4
x	functional expression of murine JE functional expression of murine JE	
	(monocyte chemoattiactant protein	_
		ely
	I linked C-C Chellokille receptor	<b>\</b>
	chromosome 9."  J BIOL CHEM, MAR 29 1996, 271 (13)  J BIOL CHEM, TEN STATES XP002043124	
	1 67661-4 11011611 2101629 11 = =	1-3,5-15
Α	see the whole document	4
v	WO 95 19436 A (UNIV CALIFORNIA ; CHARO	
X	ISRAEL (US); COUGHEIN SHAON (00)	1-3,5-15
۸	1995 see the whole document	1.
Α .	-/	
ļ		
1		
	[V] Po	stent family members are listed in annex.
X F	urther documents are listed in the continuation of box C.	
° Special	categories of cited documents of price	poument published after the international filing date only date and not in conflict with the application but to understand the principle or theory underlying the
j	ument defining the general state of the art which is not cited invent	tion
E. eati	isr document but published on or after the international cannot c	nent of particular relevance; the claimed invantion nent of particular relevance; the claimed invantion of be considered novel or cannot be considered to or an inventive step when the document is taken alone we an invention
"L" docu	ng date  ument which may throw doubts on priority claim(s) or  "Y" document which may throw doubts on priority claim(s) or  "Y" document which the publication date of another	nent of particular relevance; the classification when the
į wn		ot be considered to involve an uversite a such docu- iment is combined with one or more other, such docu- ts, such combination being obvious to a person skilled
.O. qoo	Authorit Later with a	e art. ment member of the same patent family
l lai	ter than the priority date claimed	of mailing of the international search report
Date of	the actual completion of the international search	
	14 October 1997	1 8. 02. 98
<u> </u>	Auth	orized officer
Name	and mailing address of the ISA  European Patent Office, P.B. 5818 Patentiaan 2  NL - 2280 HV Rijswijk NL - 2280 HV Rijswijk	Nauche, S
	NL - 2280 HV Risswir. Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.	NAUCIIC. J

Internz nat Application No PCT/US 97/06993

		PCT/US 97/06993
(Continua	tion) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
ategory °	Citation of document, with indication, where appropriate, of the relevant passages	
1	CHARO, I.F. ET AL.: "Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 91, 1994, WASHINGTON US, pages 2752-2756, XP002043550 cited in the application see the whole document	1-15
P,X	WO 96 39437 A (HUMAN GENOME SCIENCES INC; LI YI (US); RUBEN STEVEN M (US)) 12 December 1996 see claims 1-20	1-15
E	WO 97 32019 A (EUROSCREEN S A ;SAMSON MICHEL (FR); PARMENTIER MARC (BE); VASSART) 4 September 1997 see claims 7-89	1-15
E	WO 97 22698 A (ICOS CORP) 26 June 1997 see claims 16-29	1-15
Form PCT	//SA/210 (continuation of second sheet) (July 1992)	page 2 of 2

Ir ational application No.

PCT/US 97/06993

INTERNATIONAL SEARCH REPORT	
Box I Observations where certain claims were found unsearchable (Continu	ation of item 1 of first sheet)
Box I Observations where certain claims were found unstantion	
This International Search Report has not been established in respect of certain claims under A	Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, remark: Although claim(s) 14 (may be) and claim 1 is(are) directed to a method of treatment body, the search has been carried out and effects of the compound/composition.	of the human/animal based on the alleged
Claims Nos.:     because they relate to parts of the International Application that do not comply with an extent that no meaningful International Search can be carried out, specifically:	the prescribed requirements to such
Claims Nos.:     because they are dependent claims and are not drafted in accordance with the sec	
Box II Observations where unity of invention is lacking (Continuation of ite	em 2 of first sneet)
BOX II OBSCITED IN THE STATE OF	ition, as follows:
This International Searching Authority found multiple inventions in this international applica	
Subject 1) Claims 1-15 Subject 2) Claims 16-28	//TSA /210
For further information see continuation sheet PCT	\12W\510
As all required additional search fees were timely paid by the applicant, this Intersearchable claims.	
As all searchable claims could be searched without effort justifying an additional of any additional fee.	fee, this Authority did not invite payment
As only some of the required additional search fees were timely paid by the approximation of the required additional search fees were timely paid by the approximation of the required additional search fees were timely paid by the approximation of the required additional search fees were timely paid by the approximation of the required additional search fees were timely paid by the approximation of the required additional search fees were timely paid by the approximation of the required additional search fees were timely paid by the approximation of the required additional search fees were timely paid by the approximation of the required additional search fees were timely paid by the approximation of the required additional search fees were timely paid by the approximation of the required additional search fees were paid, specifically claims Nos.:    The required additional search fees were paid, specifically claims Nos.:	slicant, this International Search Report
4. X  No required additional search fees were timely paid by the applicant. Consequence restricted to the invention first mentioned in the claims; it is covered by claims to the invention first mentioned in the claims; it is covered by claims to the invention first mentioned in the claims; it is covered by claims to the invention first mentioned in the claims; it is covered by claims to the invention first mentioned in the claims; it is covered by claims to the invention first mentioned in the claims; it is covered by claims to the invention first mentioned in the claims; it is covered by claims to the invention first mentioned in the claims; it is covered by claims to the invention first mentioned in the claims; it is covered by claims to the claims.	ently, this International Search Report is Nos.:
I namet on Protest	is were accompanied by the applicant's protest.

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-15

A MMLR-CCR chemokine receptor , polynucleotide encoding said receptor. Antisense molecule derived from the MMLR-CCR chemokine receptor. Expression vector and recombinant host cells for the production of MMLR-CCR chemokine receptor. Antibodies immunoreactive with MMLR-CCR chemokine receptor. Uses in diagnotics and pharmaceuticals.

2. Claims: 16-28

A MPHG-CCR chemokine receptor , polynucleotide encoding said receptor. Antisense molecule derived from the MPHG-CCR chemokine receptor. Expression vector and recombinant host cells for the production of MPHG-CCR chemokine receptor. Antibodies immunoreactive with MPHG-CCR chemokine receptor. Uses in diagnotics and pharmaceuticals.

, ormation on patent family members

Interr nal Application No
PCT/US 97/06993

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9519436 A	20-07-95	AU 1679395 A EP 0740701 A JP 9508264 T US 5707815 A	01-08-95 06-11-96 26-08-97 13-01-98
WO 9639437 A	12-12-96	AU 2663295 A EP 0815137 A	24-12-96 07-01-98
WO 9732019 A	04-09-97	NONE	
WO 9722698 A	26-06-97	AU 1689297 A CA 2213331 A EP 0811063 A NO 973800 A	14-07-97 26-06-97 10-12-97 20-10-97